Levophenacylmorphan

Levophenacylmorphan
Clinical data
Other names	Levophenacylmorphan
ATC code	none;
Legal status
Legal status	BR: Class A1 (Narcotic drugs); CA: Schedule I; DE: Anlage I (Authorized scientific use only); US: Schedule I;
Identifiers
	IUPAC name (−)-3-Hydroxy-N-phenacylmorphinan;
CAS Number	10061-32-2 ;
PubChem CID	5362482;
ChemSpider	16736786 ;
UNII	7Q24AL2BR2;
KEGG	D12687 ;
CompTox Dashboard (EPA)	DTXSID90881401 ;
ECHA InfoCard	100.030.168
Chemical and physical data
Formula	C24H27NO2
Molar mass	361.485 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC[C@@]23CCN([C@@H]([C@@H]2C1)CC4=C3C=C(C=C4)O)CC(=O)C5=CC=CC=C5;
	InChI InChI=1S/C24H27NO2/c26-19-10-9-18-14-22-20-8-4-5-11-24(20,21(18)15-19)12-13-25(22)16-23(27)17-6-2-1-3-7-17/h1-3,6-7,9-10,15,20,22,26H,4-5,8,11-14,16H2/t20-,22+,24+/m0/s1 ; Key:RCYBMSQOSGJZLO-BGWNEDDSSA-N ;
	(what is this?) (verify)

Levophenacylmorphan is a morphinan derivative that acts as an opioid agonist. It has potent analgesic effects and is around 10x more potent than morphine.^[2] Adverse effects associated with its use are those of the opioids as a whole, including pruritus, nausea, respiratory depression, euphoria and development of tolerance and dependence to its effects.^[3]